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Abstract 
Background: Decisions regarding continuation or cessation of anticoagulation for patients with mechanical heart 
valves nearing the end of life represent a difficult balance of risks. The risk of suffering and disability that may result 
from thromboembolism must be weighed against the burden of continued anticoagulation therapy and the excess 
bleeding risk this confers. Data allowing quantification of the relative risks are scarce, and this translates to a lack of 
published guidance on the topic. Here we describe how this lack of guidance is impacting upon healthcare profes-
sionals and their patients through misconception of risk and under-confidence in decision-making. We also present 
local guidance we have developed that aims to improve objective risk assessment and promote individualised, 
patient-centred decision-making.
Methods: Our survey was developed by specialists in palliative care and cardiology. The survey explored respond-
ents’ conception of the risks of stopping anticoagulation for patients with mechanical heart valves at the end of life, 
as well as their ability to identify patient factors that modify this risk. Respondent decision-making, confidence, and 
readiness to accept further guidance were also explored. Healthcare professionals at two university teaching hospitals 
were invited to participate in the survey. The study population included hospital specialists, generalists, and trainees.
Results: Fifty-two healthcare professionals completed the survey, including 16 palliative care specialists. 47 (90%) of 
respondents felt poorly informed of the risks of stopping or continuing anticoagulation. 6 (12%) correctly identified 
risk of thromboembolism in patients with mechanical heart valves who are not anticoagulated. The remainder overes-
timated risk by a factor of two (18, 35%) or five (27, 52%). 49 (94%) would find further guidance on this issue helpful.
Conclusions: The healthcare professionals we surveyed felt poorly informed and ill-equipped to make decisions 
regarding anticoagulation for patients with mechanical heart valves at the end of life. They were objectively poor at 
estimating the risks involved. In the absence of robust data to support protocolisation of practice, we believe these 
decisions must be taken in conversation with the patient, taking account of individual circumstances and priorities. 
We have developed guidance for local use to support such individualised decision-making.
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Background
Valvular heart disease is a significant cause of mor-
bidity in the developed and developing world, and its 
prevalence increases linearly with age [3]. Mechanical 
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heart valve replacement remains an important thera-
peutic option for a carefully selected subset of patients 
[9]. ‘Lifelong’ anticoagulation is generally advocated for 
such patients and despite the advent of direct-acting 
oral anticoagulants, Warfarin and heparins remain the 
therapeutic agents of choice [4]. As the global popula-
tion ages, the number of patients living and dying with 
mechanical heart valves will increase.
‘End of life care’ describes the process of identify-
ing and addressing physical, psychological, emotional, 
and social needs of patients in the last 12  months 
of life [6]. As patients reach the last weeks or days of 
life, an important component of this care is review 
and agreed upon cessation of medications that are no 
longer providing benefit or may cause harm [7]. Apply-
ing this framework to the anticoagulation of patients 
with mechanical heart valves represents a particular 
challenge. Warfarin monitoring and administration 
of heparins can be burdensome, while bleeding risk is 
increased in a population with a relatively high preva-
lence of hepatic and renal dysfunction. These factors 
must be weighed against the distress and disability that 
might be conferred by thromboembolic events.
Data defining the risks of stopping anticoagulation 
are scarce, and many studies that demonstrate the 
efficacy of anticoagulation in preventing thromboem-
bolism date back to the 1960s [2]. Modern valve pros-
theses are less thrombogenic and are likely to pose less 
of a risk in the absence of anticoagulation, although 
absence of clinical equipoise has prevented empiric 
confirmation of this. Furthermore, the validity of apply-
ing data quantifying long-term risk to patients in the 
last days or weeks of life is questionable, and clinical 
trials specific to the palliative care population are rare 
[8]. Observational data on the risk of thromboembolic 
events on cessation of anticoagulation under various 
circumstances (Table 1) suggest that short term throm-
bosis risk may be rather lower than traditionally esti-
mated [1]. For example, the incidence of thrombosis 
associated with a St Jude bi-leaflet mechanical aortic 
valve prosthesis in the absence of anticoagulation has 
been estimated at 0.03% per day. For patients whose life 
expectancy is in the region of days to short weeks, this 
may support a decision to stop anticoagulation therapy.
The absence of good quality data translates to a 
lack of consensus and guidance on how to make deci-
sions regarding anticoagulation at the end of life for 
patients with mechanical heart valves. Here we present 
the results of a survey of healthcare professionals that 
demonstrates uncertainty and misconception of risk in 
the approach to such patients. We also present a local 
guideline that we have developed to support decision 
making.
Methods
A survey was designed to assess healthcare profes-
sionals’ confidence and understanding when mak-
ing decisions regarding anticoagulation at the end of 
life (see Fig.  1 for the survey in full). Questions were 
drafted by consultants in palliative care and cardiology, 
and the survey was refined following feedback from a 
focus group that was representative of the population 
to be surveyed. This survey was not formally validated. 
Respondents were asked to estimate the risk of throm-
boembolism in patients with mechanical heart valves 
in the absence of anticoagulation, and were asked to 
list factors that affect this risk for individual patients. 
Responses were reviewed for correct identification of 
risk factors as described in the literature (including 
type of valve, position of valve, and concomitant atrial 
fibrillation). Respondents were asked whether they felt 
confident in making decisions regarding anticoagula-
tion for patients with mechanical heart valves at the 
end of life, whether they would find guidance on this 
topic useful, and which hospital specialists they would 
ask for advice in the absence of such guidance.
Healthcare professionals were invited to participate if 
their current area of practice brought them into contact 
with patients with mechanical heart valves approach-
ing the end of life. Consultants, specialty trainees, and 
specialist nurses in palliative care were included, as 
were Consultants and junior doctors working in general 
medical inpatient settings across two university teach-
ing hospitals. This survey population was designed to 
assess specialist and non-specialist attitudes. The sur-
vey was circulated to target groups via SurveyMonkey®, 
and participation was voluntary. Results were analysed 
using Microsoft Excel®.
Table 1 Risk of thromboembolic events in the absence of 
therapeutic anticoagulation
Adapted from [1]
Risk of Thromboembolism Without 
Anticoagulation
Annualised Risk (%) Daily Risk (%)
Lone AF 1 0.003
Average risk AF 5 0.014
High risk AF 12 0.033
AVR (St Jude) 11 0.03
AVR (B-Shiley) 23 0.06
MVR (St Jude) 22 0.06
Multiple VR 91 0.25
Previous VTE 4 0.01
VTE in last month - 1.6
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Results
Of 310 healthcare professionals to whom the survey 
was circulated, 52 (17%) responded. This is in line with 
typical online survey response rates reported in the lit-
erature [5, 10]. Of these, 36 (69%) were foundation doc-
tors, 10 (19%) were consultant physicians, 4 (8%) were 
specialist nurses and 2 (4%) were specialty trainee doc-
tors. 16 (31%) were palliative care medicine specialists, 
while the remainder worked in other hospital medi-
cal specialties. 47 (90%) of respondents felt they were 
not well informed of the risks associated with stopping 
anticoagulation for patients with mechanical heart 
valves at the end of life, and this included 100% of pal-
liative care specialists. 49 (94%) stated that they would 
find guidance on this issue helpful. In the absence of 
such guidance, there was no consensus on which hos-
pital team should provide advice– 19 (37%) would ask 
haematology, 15 (29%) cardiology, and 15 (29%) pallia-
tive care, while 3 (6%) would ask a combination of these 
teams.
6 (12%) respondents correctly identified risk of throm-
boembolism in patients with mechanical heart valves 
who are not anticoagulated, with the remainder overesti-
mating risk by a factor of two (18, 35%) or five (27, 52%). 
14% of foundation doctors correctly estimated the risk, 
compared with 10% of consultants, and 6% of palliative 
care specialists (comprising consultants, registrars, and 
specialist nurses).
32 (62%) were able to identify at least one factor 
that affects risk of thromboembolism in patients with 
mechanical heart valves (mean number of risk factors 
identified 0.81, SD 0.76).
When considering a decision to stop anticoagulation, 
30 (58%) would favour continuation of anticoagulation 
until the oral route of administration was lost, with a fur-
ther 4 (8%) stating that parenteral anticoagulation should 
be continued until death once the oral route is lost. 21 
(40%) respondents stated that they would reconsider an 
anticoagulation prescription once a patient entered the 
last days of life, while 19 (37%) would review in the last 
weeks of life, 11 (21%) in the last months of life, and 1 
(2%) in the last hours of life.
Discussion
Deciding to stop anticoagulation for patients with 
mechanical heart valves at the end of life represents a 
difficult balance of risks, and it is a decision that must 
currently be informed by incomplete and indirectly rel-
evant data. In this study, we have described how the lack 
of local or national guidance on this subject is impacting 
upon the attitudes and decision-making of healthcare 
professionals. We found that most (including palliative 
care specialists) feel ill-informed to make this decision, 
and were objectively poor at identifying patient factors 
that should be considered. That these findings were con-
sistent across foundation doctors and consultants in pal-
liative care demonstrates that neither recency of medical 
education nor personal clinical experience make a signifi-
cant difference to preparedness.
Fig. 1 Survey developed and circulated to explore healthcare professional attitudes and understanding of the issues surrounding anticoagulation 
for patients with mechanical heart valves at the end of life
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This suggests the need for better guidance, and we 
found the overwhelming majority of healthcare profes-
sionals would be receptive to this. While acknowledging 
the paucity of quality data available to allow estimation 
of thromboembolic risk in the absence of anticoagulant 
therapy, we believe that such data as do exist support at 
least discussing cessation of anticoagulation with patients 
entering the last days or weeks of life, even for subgroups 
traditionally considered at ’high risk’ of thromboembolic 
events (such as patients with mechanical mitral valve 
prostheses).
The results of our study suggest that clinicians tend 
to over-estimate thromboembolic risk for mechanical 
heart valves and favour continuation of anticoagulation, 
typically for as long as the oral route of administration 
is available. Given the potential morbidity associated 
with a thromboembolic event, it is of course desirable 
that healthcare professionals approach decisions regard-
ing cessation of anticoagulation with consideration and 
appropriate reticence. However, harm may also result 
from inappropriate prolongation of anticoagulation ther-
apy, and we believe that in the absence of convincing data 
to support anticoagulation continuation or cessation this 
decision should be taken on a case-by-case basis follow-
ing careful discussion with the individual patient.
We believe, therefore, that a useful guideline will 
empower healthcare professionals to initiate these 
conversations with patients they have identified to be 
approaching the end of life. We have developed a guide-
line locally for those approaching this complex issue 
that encourages individualised decision making. This 
guideline includes a summary of best available data 
regarding thromboembolic risk on cessation of anti-
coagulation for a variety of patient groups as well as a 
decision-making tool to provide a more structured way 
of assessing individual risk for patients with mechanical 
heart valves (Fig. 2).
Conclusions
An important component of ’end of life care’ is the 
review and agreed upon cessation of medications that 
are no longer providing benefit, or that may cause 
harm. Making this decision with respect to anticoagu-
lation for patients with mechanical heart valve prosthe-
ses is particularly daunting due to the perceived high 
risk of thromboembolism in this cohort, and the excess 
suffering that may result from such events. This deci-
sion is further complicated by a lack of guidance on 
how it should be approached. Data to inform this deci-
sion are scarce, but where available suggest that when 
Fig. 2 Summary ’decision aid’ from local guideline on managing anticoagulation for patients with mechanical heart valves approaching the end of 
life
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adjusted to a timescale relevant to patients in the last 
days or weeks of life, thromboembolic risk may in fact 
not be high enough to justify continuation of anticoag-
ulation under all circumstances.
Our study demonstrates that healthcare profession-
als lack confidence in making such decisions, are objec-
tively poor at assessing the relevant risks for a given 
patient (with a consistent tendency to over-estimate 
thromboembolic risk), and may therefore be exposing 
patients to harm.
We suggest that although empiric data to inform deci-
sions relating to anticoagulation cessation in patients 
with mechanical heart valve prostheses at the end of life 
are limited, patient care could still be improved by the 
development of guidance drawing on expert opinion 
and available observational data. We have developed a 
guideline for local use that aims to empower healthcare 
professionals to initiate conversations with patients 
regarding their anticoagulation as they approach the 
end of life, with the objective of reaching an informed 
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